Written informed consent was obtained to participate in the study and HIPAA authorization for release of personal health information. Subjects is willing and able to comply with study procedures based on the judgment of the investigator.
Age ≥ 18 years at the time of consent.
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1 Histological or cytological evidence/confirmation of unresectable, borderline resectable, or metastatic (basal-like and classical) pancreatic adenocarcinoma.
The subject must consent to a mandatory pre-study biopsy if archival tissue is not available or sufficient.
Subjects may have received prior standard-of-care (SOC) neoadjuvant therapy and may have received up to two cycles of first-line FOLFIRINOX or NALIRIFOX.
A subject with prior brain metastasis may be considered if they have completed their treatment for brain metastasis at least 4 weeks prior to study treatment have been off of corticosteroids for ≥ 2 weeks and are asymptomatic.
You may not be if
Disease is not measurable according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1
Not having histological or cytological evidence/confirmation of metastatic pancreatic adenocarcinoma.
Treatment with any investigational drug or prior cancer treatment within 28 days prior to study treatment
Clareo Health | Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
